Cargando…
Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination
BACKGROUND: Patients with multiple myeloma have unpredictable responses to vaccination for COVID-19. Anti-spike antibody levels can determine which patients develop antibodies at levels similar to healthy controls, and are a known correlate of protection. CASE REPORT: A multiple myeloma patient deve...
Autores principales: | Stampfer, Samuel D., Goldwater, Marissa-Skye, Bujarski, Sean, Regidor, Bernard, Zhang, Wenjuan, Feinstein, Aaron J., Swift, Regina, Eshaghian, Shahrooz, Vail, Eric, Berenson, James R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654462/ https://www.ncbi.nlm.nih.gov/pubmed/34909634 http://dx.doi.org/10.1016/j.clinpr.2021.100130 |
Ejemplares similares
-
Loss of anti‐spike antibodies following mRNA vaccination for COVID‐19 among patients with multiple myeloma
por: Stampfer, Samuel D., et al.
Publicado: (2023) -
Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients
por: Stampfer, Samuel D., et al.
Publicado: (2021) -
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
por: Stampfer, Samuel D., et al.
Publicado: (2021) -
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
por: Goldwater, Marissa-Skye, et al.
Publicado: (2023) -
Use of Shockwave in Heavily Calcified Coronary Lesion: Breakthrough or Myth?
por: Lee, Sang Yeub
Publicado: (2022)